Lonza and Touchlight Enter mRNA Collaboration

Publication
Article
BP ElementsBioPharm International's BP Elements, September 2022
Volume 1
Issue 9

Touchlight will expand Lonza’s end-to-end offering for mRNA manufacturing with an additional, differentiated source of DNA raw material.

Lonza announced a collaboration with Touchlight, a biotechnology company specializing in enzymatic DNA production, on Sept. 6, 2022. Under the collaboration, Lonza will integrate Touchstone’s differentiated source of DNA in its messenger RNA (mRNA) therapeutics and vaccines, while Touchstone will widen the reach of its novel doggybone DNA technology.

According to a company press release, Touchlight’s enzymatic DNA technology is a linear, covalently closed DNA vector. It is produced through an enzymatic manufacturing process, which is designed to maximize speed, scale, and purity. This technology presents an alternative to working with plasmid DNA when working with Lonza’s mRNA manufacturing offering.

“The strategic collaboration with Touchlight enables Lonza to further enhance its position as a global leader in mRNA manufacturing,” said André Goerke, vice-president and business unit head, mRNA, Lonza, in the press release. “We can now provide our customers with a strong foundation to deliver an end-to-end offering that includes access to a novel synthetic DNA technology. Such an integrated solution can prove beneficial in speeding up time to market, which is critical in the fast-paced industry of mRNA manufacturing.”

“We are delighted to provide Touchlight customers the benefits of an end-to-end mRNA offering through our collaboration with Lonza,” said Karen Fallen, CEO, Touchlight DNA Services, in the press release. “Lonza is the leading [contract manufacturing and development organization] in mRNA manufacturing and has an established, global mRNA manufacturing network. The alliance allows both companies to innovate and to extend their offering on a global level.”

Source: Lonza

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
© 2025 MJH Life Sciences

All rights reserved.